This should be a very interesting year for Wyeth ( WYE). The Madison, N.J., drugmaker could hear from the Food and Drug Administration on as many as six new products ranging from a kidney-cancer drug to a treatment for schizophrenia. The first word should come sometime this month, when the FDA is expected to rule on the antidepressant Pristiq. "Wyeth has an impressive portfolio of drugs and has built a decent research pipeline over the last several years," says Brandon Troegle, an analyst for the research firm Morningstar in a recent review of the company. "While we aren't incredibly enthusiastic about any particular drug, the breadth of the pipeline is significant." Wall Street has taken notice of Wyeth's prospects. Three months ago, it received eight buy recommendations and 12 hold ratings, according to Thomson Financial data. Now 12 analysts say buy the stock and seven have hold ratings. Until any new drugs contribute significant new sales, Wyeth will continue to rely on old favorites -- the pneumococcal disease vaccine Prevnar, Enbrel for rheumatoid arthritis and other diseases, the antidepressant Effexor XR, and Protonix, for severe heartburn -- to carry much of the load. Clearly, the full profit potential of new products won't be reflected this year, or even next year. New drugs could produce "pretty substantial" sales, says Jason Napodano of Zacks Investment Research. A best-case sales scenario "could set the stage" for accelerated growth in 2009 and 2010, says Napodano, who has a hold rating and a $55 price target.